Cleveland BioLabs Receives First US Patent for Radiation Protection Drug

Cleveland BioLabs, Inc. announced Wednesday that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled “Modulating Apoptosis” covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502.
Marketwire